Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 November 2024 | Story Jacky Tshokwe | Photo Supplied
BUAN Delegates
Botswana University of Agriculture and Natural Resources (BUAN) delegates that recently visited the University of the Free State to solidify a collaboration.

During an inspiring journey, a delegation from the University of the Free State (UFS) recently visited the Botswana University of Agriculture and Natural Resources (BUAN) with an ambitious goal: to solidify a collaboration that was sparked during the visit of BUAN’s Vice-Chancellor to the UFS and subsequent discussions in Namibia. The atmosphere was one of shared purpose and excitement as the UFS representatives, led by the Dean of the Faculty of Natural and Agricultural Sciences, the Vice-Dean: Agriculture, and the Vice-Dean: Postgraduate and Research, embarked on this significant academic endeavour.

This visit was not just a formal gesture, it was a step towards tangible, mutual benefits for students and staff of both institutions. The discussions between the UFS and the BUAN leadership, which centred around possibilities for student and staff exchanges and shared access to specialised equipment, pointed to the potential of creating a dynamic bridge between South African and Botswana academia. This partnership envisions collaborative supervision of postgraduate students, creating opportunities for intellectual growth that transcends borders. The two universities also explored joint funding applications and research avenues, with particular interest in BUAN’s innovative Meat Institute and AgroVolts solar panel project. Seeing the BUAN’s progress in renewable energy left the UFS team particularly impressed, reflecting the possibilities for sustainable development and resource-sharing that a partnership could yield.

During the discussions, the UFS delegation had a pivotal meeting with the BUAN’s Acting Deputy Vice-Chancellor: Academic and Research, Prof Samodimo Ngwako, who had previously visited the UFS. His familiarity with the UFS’ resources and vision made him an invaluable advocate for bridging the two institutions, highlighting how their strengths could complement each other. Prof Ngwako’s insights helped BUAN staff visualise the meaningful exchange of expertise and resources that could benefit both student bodies and contribute to third-stream income generation.

With the way forward clear, both the UFS and BUAN teams agreed on ‘quick steps’ to launch the collaboration – the swift signing of a Memorandum of Understanding (MoU), followed by the first exchange of students and staff, and the launch of co-supervised research projects. While specific timelines and milestones are to be confirmed post-MoU, both teams are keen on joint funding applications, especially in areas relevant to agricultural and natural resources both within Africa and beyond. This partnership, once formalised, is expected to solidify both universities as leading research hubs in agriculture and natural resources, advancing each institution’s standing on the continent.

Reflecting on the visit, the UFS delegation felt a deep sense of optimism. The collaboration between the UFS and the BUAN aligns seamlessly with the UFS’ broader vision for strengthening ties with African universities, showcasing a forward-thinking approach to partnerships. As the journey towards meaningful collaboration progresses, the shared enthusiasm witnessed at the BUAN serves as a hopeful reminder that academia – when united by common goals – can drive impactful change for students, faculty, and communities on both sides of the border.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept